371 related articles for article (PubMed ID: 26534766)
1. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.
Cahill KE; Morshed RA; Yamini B
Neuro Oncol; 2016 Mar; 18(3):329-39. PubMed ID: 26534766
[TBL] [Abstract][Full Text] [Related]
2. The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.
Shi P; Xu J; Cui H
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373484
[TBL] [Abstract][Full Text] [Related]
3. Oncrasin targets the JNK-NF-κB axis to sensitize glioma cells to TNFα-induced apoptosis.
Gupta P; Dixit D; Sen E
Carcinogenesis; 2013 Feb; 34(2):388-96. PubMed ID: 23125226
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA
Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590
[TBL] [Abstract][Full Text] [Related]
5. Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.
Raychaudhuri B; Han Y; Lu T; Vogelbaum MA
J Neurooncol; 2007 Oct; 85(1):39-47. PubMed ID: 17479228
[TBL] [Abstract][Full Text] [Related]
6. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.
Gray GK; McFarland BC; Nozell SE; Benveniste EN
Expert Rev Neurother; 2014 Nov; 14(11):1293-306. PubMed ID: 25262780
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.
Li ZY; Li QZ; Chen L; Chen BD; Wang B; Zhang XJ; Li WP
Neurochem Res; 2016 Dec; 41(12):3192-3205. PubMed ID: 27632183
[TBL] [Abstract][Full Text] [Related]
8. Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.
Lindemann C; Marschall V; Weigert A; Klingebiel T; Fulda S
Neoplasia; 2015 Jun; 17(6):481-9. PubMed ID: 26152356
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
10. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment.
Nandhu MS; Kwiatkowska A; Bhaskaran V; Hayes J; Hu B; Viapiano MS
Oncogene; 2017 Aug; 36(34):4875-4886. PubMed ID: 28414309
[TBL] [Abstract][Full Text] [Related]
12. Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.
Dhruv HD; Roos A; Tomboc PJ; Tuncali S; Chavez A; Mathews I; Berens ME; Loftus JC; Tran NL
J Neurooncol; 2016 Feb; 126(3):397-404. PubMed ID: 26559543
[TBL] [Abstract][Full Text] [Related]
13. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
15. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
16. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.
Dhandapani KM; Mahesh VB; Brann DW
J Neurochem; 2007 Jul; 102(2):522-38. PubMed ID: 17596214
[TBL] [Abstract][Full Text] [Related]
17. CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Wang Y; Bao G; Zhang M; Xiang J; Zhou H; Wahafu A; Wu W; Ma X; Huo L; Bai X; Xie W; Liu P; Wang M
Exp Cell Res; 2022 May; 414(1):113077. PubMed ID: 35219647
[TBL] [Abstract][Full Text] [Related]
18. NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.
Xiang J; Alafate W; Wu W; Wang Y; Li X; Xie W; Bai X; Li R; Wang M; Wang J
Cell Death Dis; 2022 Jan; 13(1):58. PubMed ID: 35031599
[TBL] [Abstract][Full Text] [Related]
19. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
20. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
Wang H; Li L; Yin L
Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
